Elamipretide FDA Approval: Current Status and What It Means

Elamipretide (brand name Forzinity) is not approved by the FDA for commercial sale in the United States, and the only condition the agency has formally reviewed it for is Barth syndrome, an ultra-rare genetic mitochondrial disorder. Its regulatory history includes a refusal-to-file on the first marketing application, a resubmitted application with a PDUFA target action date, and a lengthy back-and-forth over how much evidence is enough. Until the FDA grants marketing approval, elamipretide remains an investigational drug that patients can usually access only through clinical trials or expanded access programs.

That legal status is easy to lose track of, because elamipretide is widely sold online as a "research peptide" alongside dozens of other compounds. A research chemical listing is not an approval, and it comes with no guarantee of purity, dose accuracy, or sterility.

What Elamipretide Actually Is

Elamipretide is a synthetic tetrapeptide designed to accumulate inside mitochondria and bind to cardiolipin, a phospholipid on the inner mitochondrial membrane. Scientists believe that interaction helps stabilize mitochondrial energy production, which is why the drug has been studied mainly in conditions rooted in mitochondrial dysfunction.

The molecule has carried several names across two decades of development: SS-31, MTP-131, and now elamipretide. Stealth BioTherapeutics is the company developing it. If you search ss 31 fda approval, you are looking at the same compound under its original laboratory code name, and the regulatory answer is identical.

Elamipretide FDA Approval Timeline: The Stages That Matter

Approval is not a single event — it is a sequence of gates. The table below shows the stages the FDA uses and where elamipretide has reached in that sequence.

At every stage, the FDA is asking the same question: does the evidence show the drug works for the specific population studied? A PDUFA date is only a target, and the agency can act earlier, extend the review, or decline to approve.

Why the FDA Has Been Cautious

Barth syndrome affects an estimated 1 in 300,000 to 400,000 births, almost always boys, and it currently has no FDA-approved therapy. The unmet need is real, but that same rarity makes it hard to generate the kind of data the FDA normally expects.

• Small evidence base. The Barth syndrome program, known as TAZPOWER, enrolled roughly a dozen patients in a crossover design, which limits statistical power.
• Mixed results in other indications. A Phase 3 study in primary mitochondrial myopathy reportedly did not meet its primary endpoint, and results in eye disease have come from early-stage trials.
• The substantial evidence standard. The FDA generally wants two adequate and well-controlled trials, or one trial plus confirmatory evidence, before it approves a new drug.
• Durability questions. Reviewers have asked whether any observed benefit persists over time and whether it translates into meaningful functional improvement.

Regulators can be flexible with ultra-rare diseases, and patient advocacy groups have pressed hard for access. Even so, flexibility does not remove the requirement to show a real effect.

What Elamipretide Is Not Approved For

Even in a best-case scenario, any future approval would be narrow. Elamipretide is not a supplement ingredient, and no FDA approval would extend to wellness or performance use.

Peptides sold on gray-market sites rarely have an approval behind them. Searches for is aod-9604 fda approved and cjc-1295 ipamorelin fda approved both end in the same place: no approved human use.

Access, Cost, and Safety

Because the drug is not commercially available, elamipretide cost is usually discussed in the context of trial participation or expanded access rather than pharmacy pricing. There is no published U.S. list price for a medicine that has not been approved.

1. Clinical trials. Enrolling in a study is the most common route, and trial drugs are typically provided at no cost to participants.
2. Expanded access (compassionate use). A physician can request the drug from the manufacturer for a specific patient; the company is not obligated to say yes.
3. Waiting for FDA action. If approval ever comes, insurance coverage and specialty pharmacy distribution would follow the label.

On safety, the most frequently reported side effect in trials has been injection-site reactions. Long-term safety data in Barth syndrome remain limited, and any decision to use an investigational peptide should be made with a physician who understands the patient's mitochondrial diagnosis.

Self-treating with research-grade elamipretide is not advisable. Those products are not manufactured under FDA standards, so purity, potency, and sterility are unverified, and the labeled amount of peptide may not match what is actually in the vial.

How to Check the Latest Elamipretide FDA Status

Target action dates move constantly. Anyone who follows pipeline news knows this — the same is true of retatrutide fda approval chatter in obesity medicine, where review timelines routinely shift.

For elamipretide specifically, rely on the FDA's own sources rather than forums or vendor pages: Drugs@FDA lists application status and review documents, the Orange Book shows what is actually approved, and an FDA press announcement would confirm an approval the day it happens.

Here is the bottom line. Elamipretide is not FDA-approved for any indication in the United States as of the most recent public FDA action. Barth syndrome is the only condition for which an FDA marketing application has been submitted for elamipretide. If the FDA does approve it, Forzinity would become the first approved therapy for Barth syndrome, and it still would not be a legal supplement or a performance drug.